What Have We Learned About Ceftazidime-Avibactam?
Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses the significance of the findings of her research on Ceftazidime-Avibactam.
Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses the significance of the findings of her research on Ceftazidime-Avibactam.
Interview Transcript (slightly modified for readability)
“The findings of this research are significant because there’s not really a lot of data on this antibiotic [Ceftazidime-Avibactam] yet. It’s only been out a year and a half at this point,* and it’s only been approved for two indications: intra-abdominal infections and urinary tract infections. There hasn’t been anything reported, as of yet, on [the approval of the antibiotic to treat] other types of infections. I did recently see a case series of three patients that was reported, that was in other infections, but that’s all that’s been published so far in the US.
We really need data to show whether or not it’s good [to treat other infection]. We can’t say that for sure yet, but we need something to go off of to know if we should be using this.”
This interview was conducted at ID Week 2016.
